Oral Abstract Session 01 - Global HIV Vaccine Enterprise

Recommendations

Info

PLENARY SESSIONS 28 Plenary Sessions Plenary 03: New Concepts in Immune Induction PL03.03 Experimental HIV-Vaccines Induce Immunological Memory in Murine and Human NK Cells S. Paust 1 1 Harvard Medical School, Boston, MA, USA Using mice and humanized mice, we found that a single vaccination with replication-deficient experimental HIV-1 vaccines results in vaccination-dependent NK cell mediated recall responses to HIV-1 group antigen and envelope. AIDS Vaccine 2012
Symposium 01: Exploiting the Innate Immune Response S01.01 Development of Dendritic Cell-based Prophylactic and Therapeutic HIV Vaccine Y. Levy 1 , A. Palucka 2 1 CHU Henri Mondor, Creteil, France; 2 Baylor Institute for Immunology Research, Dallas, TX, USA Dendritic cells (DCs), as the most potent antigen-presenting cells, have a pivotal role in the initiation, regulation and maintenance of immune responses against cancers and pathogens. They form a unique link between the innate and adaptive immune system. DC subsets display different receptors and express different sets of cytokines/chemokines, leading to distinct immunological outcomes. For example, CD14+ dermal DCs preferentially control humoral immunity while epidermal DCs (Langerhans cells) preferentially induce cellular immunity. Several studies have tested ex vivo generated DC loaded with inactivated HIV or HIV peptides. We report the results of the DALIA trial testing autologous DCs generated ex vivo from monocytes cultured with GM-CSF/IFN-alpha and loaded with five lipidated HIV antigens (LIPO5). Vaccination elicited polyfunctional HIV-specific responses associated with a reduced peak of viral rebound upon HAART interruption. Targeting antigens directly to DCs via anti- DC receptor monoclonal antibody-antigen fusion proteins (FP) is another promising approach to HIV vaccine development. We are developing anti-DC FP with the objective to target Langerin, CD40, DCIR and Lox-1 receptors. In vitro, CD40 and DCIR-HIV FP expanded a broad repertoire of Ag specific and multifunctional CD4+ and CD8+ T cells from HIV-infected patients. The final goal is to combine FPs targeting HIV Env and HIV T cell epitopes to different populations of DC with the aim to elicit B and T cell responses. These FP are now being tested in NHP in prime boost strategies in combination with MVA and Pox vectors. S01.02 Symposia Sessions Adjuvants Influence the Magnitude, Quality and Durability of HIV Env Specific Humoral Immunity in Non-human Primates J.R. Francica 3 , G. Tomaras 1 , M. Alam 1 , G. Ferrari 1 , J. Mascola 3 , D.T. O’Hagan 2 , R. Seder 3 1 Duke Human Vaccine Institute, Durham, NC, USA; 2 Novartis Vaccines, Cambridge, MA, USA; 3 Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA An effective preventive vaccine against HIV will require potent and durable HIV Env specific antibody responses. Accordingly, immune adjuvants will be critical for optimizing HIV Env immunity with protein-based vaccines. We performed a comparative analysis of how adjuvants influence HIV Env specific immunity in non-human primates (NHP) when administered with a trimeric HIV Clade C Env protein. The adjuvants chosen were based either on their extensive clinical use (alum, MF 59) or their ability to mediate adaptive immunity through distinct toll-like receptor dependent or other innate pathways. NHP were immunized at week 0, 4, 12 and 24 with HIV Env protein and Alum or MF59 with or without TLR 4 (MPL) or TLR 7 ligands or Poly ICLC or ISCOMs. A comprehensive analysis of HIV binding titer, neutralization against Tier 1 and 2 viruses, CD4BS, ADCC, avidity and serum and mucosal IgG and IgA were performed. Moreover, HIV Env specific B cells were sorted and the Ig loci analyzed using high-throughput deep sequencing to determine the gene family usage, and levels of somatic mutation. Overall, the data presented highlight how adjuvants alter both the magnitude and quality of HIV Env specific antibody responses. AIDS Vaccine 2012 29 SYMPOSIA SESSIONS
Page 2 and 3: AIDS Vaccine 2012 PROGRAM AT A GLAN
Page 4 and 5: AIDS Vaccine 2012 Partners www.alli
Page 6 and 7: CONFERENCE ORGANIZERS Conference Or
Page 8 and 9: CONFERENCE ORGANIZERS Conference Or
Page 10 and 11: SCHOLARSHIP RECIPIENTS Awards and S
Page 12 and 13: SCHOLARSHIP RECIPIENTS Awards and S
Page 14 and 15: PROGRAM / MONDAY 2 Program Monday,
Page 16 and 17: PROGRAM / MONDAY 4 Program 11:00 -
Page 22 and 23: PROGRAM / TUESDAY 10 Program Tuesda
Page 24 and 25: PROGRAM / TUESDAY 12 Program 11:45
Page 26 and 27: PROGRAM / TUESDAY 14 Program 13:30
Page 28 and 29: PROGRAM / TUESDAY 16 Program Poster
Page 30 and 31: PROGRAM / TUESDAY 18 Program AIDS V
Page 32 and 33: PROGRAM / WEDNESDAY 20 Program Wedn
Page 34 and 35: 22 AIDS Vaccine 2012
Page 36 and 37: PLENARY SESSIONS 24 Plenary Session
Page 38 and 39: PLENARY SESSIONS 26 Plenary Session
Page 42 and 43: SYMPOSIA SESSIONS 30 Symposia Sessi
Page 66 and 67: ORAL ABSTRACT SESSIONS 54 Oral Abst
Page 90 and 91:
ORAL ABSTRACT SESSIONS 78 Oral Abst
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
92 AIDS Vaccine 2012
Page 106 and 107:
POSTERS 94 AIDS Vaccine 2012
Page 108 and 109:
POSTERS 96 Posters Topic 1: Adjuvan
Page 110 and 111:
POSTERS 98 Posters Topic 1: Adjuvan
Page 112 and 113:
POSTERS Posters Topic 1: Adjuvants,
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
POSTERS Posters Topic 2: Animal Mod
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
POSTERS Posters Topic 3: B Cell Imm
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
POSTERS Posters Topic 4: Clinical V
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
POSTERS Posters Topic 5: HIV Transm
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
POSTERS Posters Topic 6: Immunogene
Page 192 and 193:
POSTERS Posters Topic 7: Innate Imm
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
POSTERS Posters Topic 8: Mucosal Im
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
POSTERS Posters Topic 9: Non-Vaccin
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
POSTERS Posters Topic 10: Social/Et
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
POSTERS Posters Topic 11: T Cell Im
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
POSTERS Posters Topic 12: Vaccine C
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
POSTERS Posters Topic 13: Pediatric
Page 290 and 291:
AUTHOR INDEX Author Index Brander,
Page 292 and 293:
AUTHOR INDEX Author Index Guan, Y .
Page 294 and 295:
AUTHOR INDEX Author Index Lucas, J.
Page 296 and 297:
AUTHOR INDEX Author Index Quinn, T
Page 298 and 299:
AUTHOR INDEX Author Index Wendel-Ha
Page 300 and 301:
Notes 288
Page 302 and 303:
Notes 290
Page 305:
Poster Session 1 - Monday, 10 Septe
show all

Oral Abstract Session 01 - Global HIV Vaccine Enterprise

Create successful ePaper yourself

Delete template?

Save as template?